These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
250 related articles for article (PubMed ID: 19753127)
1. Mycophenolic acid formulations in adult renal transplantation - update on efficacy and tolerability. Golshayan D; Pascual M; Vogt B Ther Clin Risk Manag; 2009 Aug; 5(4):341-51. PubMed ID: 19753127 [TBL] [Abstract][Full Text] [Related]
2. Mycophenolate mofetil: safety and efficacy in the prophylaxis of acute kidney transplantation rejection. Dalal P; Grafals M; Chhabra D; Gallon L Ther Clin Risk Manag; 2009 Feb; 5(1):139-49. PubMed ID: 19436616 [TBL] [Abstract][Full Text] [Related]
3. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes. Budde K; Glander P; Krämer BK; Fischer W; Hoffmann U; Bauer S; Grohmann J; Neumayer HH; Arns W Transplantation; 2007 Feb; 83(4):417-24. PubMed ID: 17318074 [TBL] [Abstract][Full Text] [Related]
4. No relevant pharmacokinetic interaction between pantoprazole and mycophenolate in renal transplant patients: a randomized crossover study. Rissling O; Glander P; Hambach P; Mai M; Brakemeier S; Klonower D; Halleck F; Singer E; Schrezenmeier EV; Dürr M; Neumayer HH; Budde K Br J Clin Pharmacol; 2015 Nov; 80(5):1086-96. PubMed ID: 25913040 [TBL] [Abstract][Full Text] [Related]
5. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Staatz CE; Tett SE Clin Pharmacokinet; 2007; 46(1):13-58. PubMed ID: 17201457 [TBL] [Abstract][Full Text] [Related]
6. Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure. Tett SE; Saint-Marcoux F; Staatz CE; Brunet M; Vinks AA; Miura M; Marquet P; Kuypers DR; van Gelder T; Cattaneo D Transplant Rev (Orlando); 2011 Apr; 25(2):47-57. PubMed ID: 21190834 [TBL] [Abstract][Full Text] [Related]
7. Similar efficacy and safety of enteric-coated mycophenolate sodium (EC-MPS, myfortic) compared with mycophenolate mofetil (MMF) in de novo heart transplant recipients: results of a 12-month, single-blind, randomized, parallel-group, multicenter study. Kobashigawa JA; Renlund DG; Gerosa G; Almenar L; Eisen HJ; Keogh AM; Lehmkuhl HB; Livi U; Ross H; Segovia J; Yonan N; J Heart Lung Transplant; 2006 Aug; 25(8):935-41. PubMed ID: 16890114 [TBL] [Abstract][Full Text] [Related]
8. Enteric-coated mycophenolate sodium: therapeutic equivalence to mycophenolate mofetil in de novo renal transplant patients. Sollinger H Transplant Proc; 2004 Mar; 36(2 Suppl):517S-520S. PubMed ID: 15041399 [TBL] [Abstract][Full Text] [Related]
9. A prospective analysis of the effects of enteric-coated mycophenolate sodium and mycophenolate mofetil co-medicated with a proton pump inhibitor in kidney transplant recipients at a single institute in China. Xu L; Cai M; Shi BY; Li ZL; Li X; Jin HL Transplant Proc; 2014 Jun; 46(5):1362-5. PubMed ID: 24935300 [TBL] [Abstract][Full Text] [Related]
10. Enteric-coated mycophenolate sodium: a review of its use in the prevention of renal transplant rejection. Sanford M; Keating GM Drugs; 2008; 68(17):2505-33. PubMed ID: 19016576 [TBL] [Abstract][Full Text] [Related]
11. Comparison of inosine-monophosphate-dehydrogenase activity in patients with enteric-coated mycophenolate sodium or mycophenolate mofetil after renal transplantation. Rath T; Küpper M Transplant Proc; 2009; 41(6):2524-8. PubMed ID: 19715967 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and variability of mycophenolic acid from enteric-coated mycophenolate sodium compared with mycophenolate mofetil in de novo heart transplant recipients. Hummel M; Yonan N; Ross H; Miller LW; Sechaud R; Balez S; Koelle EU; Gerosa G; Clin Transplant; 2007; 21(1):18-23. PubMed ID: 17302587 [TBL] [Abstract][Full Text] [Related]
13. Evalutation of mycophenolic acid systemic exposure by limited sampling strategy in kidney transplant recipients receiving enteric-coated mycophenolate sodium (EC-MPS) and cyclosporine. Capone D; Tarantino G; Kadilli I; Polichetti G; Basile V; Federico S; Sabbatini M Nephrol Dial Transplant; 2011 Sep; 26(9):3019-25. PubMed ID: 21317409 [TBL] [Abstract][Full Text] [Related]
14. Pharmacology and toxicology of mycophenolate in organ transplant recipients: an update. Staatz CE; Tett SE Arch Toxicol; 2014 Jul; 88(7):1351-89. PubMed ID: 24792322 [TBL] [Abstract][Full Text] [Related]